Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Stella Pharma Corporation (4888.T)
Osaka, JP
Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy (BNCT). Their product lineup includes SPM-011, a boron-containing drug designed for BNCT, which is utilized in the treatment of head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma, and angiosarcoma. Founded in 2007, Stella Pharma Corporation maintains its headquarters in Osaka, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.49% | -20.88% | -36.46% | +15.69% | +54.68% | +94.81% | +28.26% | +18.00% | -9.63% | -52.09% | -52.09% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-66.4% Q1'26: -91.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-443.8% Q1'26: -215.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-102.4% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-231.6% Q1'26: -395.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-213.6% Q1'26: -277.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.9% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.04× Q1'26: -0.79× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
|---|---|---|---|
| Revenue |
205.97M
est: 205.00M (+0.5%)
|
100.10M
est: 223.00M (-55.1%)
|
229.07M
est: 192.00M (+19.3%)
|
| EBITDA |
-649.12M
est: -168.23M (-285.9%)
|
-707.77M
est: -183.00M (-286.8%)
|
-771.73M
est: -157.56M (-389.8%)
|
| EBIT |
-680.57M
est: -169.71M (-301.0%)
|
-741.90M
est: -184.61M (-301.9%)
|
-806.78M
est: -158.95M (-407.6%)
|
| Net Income |
-659.24M
est: -1.10B (+40.2%)
|
-767.72M
|
-778.82M
est: -1.09B (+28.4%)
|
| SGA |
538.27M
est: 571.81M (-5.9%)
|
537.42M
est: 622.02M (-13.6%)
|
624.79M
est: 535.55M (+16.7%)
|
| EPS |
-23.95
est: -33.00 (+27.4%)
|
-26.77
|
-26.97
est: -32.60 (+17.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hirotaka Ogawa | Executive Officer & GM of General Affairs | — | — |
| Hisashi Sakoi | General Manager of Administration Division | — | — |
| Koki Uehara | President & Chairman | — | male |
| Minoru Hasegawa | Accounting Manager | — | — |
| Naoshi Igami | General Manager of Administration Division | — | — |
| Takahiro Kido | GM of Corporate Planning Department & Director | — | male |
| Toshimitsu Hayashi | GM of Pharmaceutical Affairs & Clinical Development Department and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4888.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
